A New Neurotech Startup Launches to Rival Sam Altman’s Merge Labs

Bridge Neurotech has officially emerged as a new player in the brain-computer interface (BCI) sector, positioning itself as a direct competitor to Merge Labs, a venture backed by OpenAI CEO Sam Altman. The startup is focused on developing a non-invasive, wearable BCI device that utilizes ultrasound technology to monitor and interact with neural activity. Unlike traditional invasive implants that require surgical intervention, Bridge Neurotech aims to leverage the precision of ultrasound to provide high-resolution brain data through a consumer-friendly wearable form factor. This approach represents a significant shift in the neurotechnology landscape, as companies race to make neural interfaces more accessible and safer for widespread use. By challenging established players like Merge Labs, Bridge Neurotech hopes to accelerate the development of practical BCI applications, potentially transforming how humans interact with digital systems and manage neurological health through advanced, non-surgical monitoring capabilities.